New Jersey 2024-2025 Regular Session

New Jersey Senate Bill S2741

Introduced
2/15/24  

Caption

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

Impact

The enactment of S2741 would amend New Jersey's consumer fraud laws, elevating violations associated with this bill to unlawful practices. Penalties for violations are significant, with first offenses carrying a monetary penalty of up to $10,000, and subsequent offenses increasing to $20,000. Additionally, offenders may face cease and desist orders from the Attorney General, along with punitive damages and the possibility of treble damages, thereby enhancing the legal implications for sellers who misadvertise their products.

Summary

S2741, introduced in New Jersey, aims to regulate the sale and advertisement of certain products that allude to controlled dangerous substances or analogs. Specifically, the bill prohibits the sale of any merchandise that features advertisements linking it to controlled substances when directed at consumers under 18 years of age, or when the product is food, beverage, or meant for ingestion or inhalation. This regulatory measure is envisioned to safeguard the youth from potential influence by drug-related marketing tactics.

Contention

Debate surrounding S2741 is likely to include concerns regarding the balance between promoting public health and protecting commercial free speech. Proponents of the bill argue that it is essential for reducing drug-related influences on younger audiences, thereby contributing to more robust public health outcomes. Conversely, opponents may assert that the bill overextends government intervention into advertising and commercial practices, potentially stifling legitimate business interests and infringing on rights to free expression in marketing.

Companion Bills

NJ A366

Same As Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ S2336

Carry Over Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ A3725

Carry Over Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

Previously Filed As

NJ S2336

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ A3725

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ A366

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

NJ S166

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ A784

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ A2174

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ A714

Allows certain drug dealing offenses to be graded by "units," rather than weight, of controlled dangerous substances.

NJ A5488

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances; requires reporting of xylazine prescriptions.

NJ HB3567

Controlled dangerous substances; adding to list of Schedule I controlled substances; revocation or suspension of registrations; written orders; repealers; emergency.

NJ AB3029

Controlled substances.

Similar Bills

CA SB921

Political Reform Act of 1974: digital political advertisements.

CA AB868

Political Reform Act of 1974: digital political advertisements.

CA AB794

Cannabis: advertising and marketing restrictions.

CA AB2716

Cannabis: advertisements: highways.

CA AB1175

Outdoor advertising displays: redevelopment agency project areas.

CA AB2546

Commercial email advertisements.

CA SB405

Outdoor advertising displays: exemptions: City of Artesia.

CA AB1982

Outdoor advertising displays: exemptions: City of Artesia.